The U.K.'s National Institute for Health and Care Excellence (NICE) published its final appraisal determination recommending Blincyto (blinatumomab), the bispecific antibody from Thousand Oaks, Calif.-based Amgen Inc. as an option for treating adults with Philadelphia-chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia, on the basis of the discount agreed in the patient access scheme.